The trend of traditional Chinese medicine sector is active, Xinguang Pharmaceutical Co., Ltd. rose sharply, and Essence Pharmaceutical Co., Ltd., Guangyuyuan, etc. rose by the daily limit_ Securities Times Network

The traditional Chinese medicine sector was active in intraday trading on the 23rd. As of press time, Xinguang Pharmaceutical rose about 17%, and the stock rose by the daily limit; Long Shenrong rose about 11%, Essence Pharmaceutical, Panlong Pharmaceutical, Guangyuyuan, Kangyuan The daily limit of pharmaceutical companies, Zhongsheng Pharmaceutical rose more than 9%, and Tongrentang rose nearly 7%.

On the news, the 9th edition of the new coronary pneumonia diagnosis and treatment plan proposes to strengthen the use of traditional Chinese medicine, such as adding acupuncture and other treatment content, and traditional Chinese medicine has become an important tool in the “anti-epidemic toolkit”. Its role in anti-epidemic cannot be ignored, and its strategic position is also Continuous improving.

Debon Securities said that since the outbreak of the epidemic, domestic and foreign clinics have continuously explored the therapeutic effects of new and old antiviral drugs, from the early clinical references of remdesivir and various neutralizing antibodies to Merck’s Molnupiravir and Pfizer’s Paxlovid. With the emergence of small molecule oral drugs, the new crown treatment drugs have gradually developed into more efficient and more convenient drugs. On the basis of domestic western medicine treatment, more traditional Chinese medicine treatment plans have been explored. The “three medicines and three prescriptions” represented by Lianhua Qingwen Capsules have been clinically proven to have obvious therapeutic effects, and they have made great achievements in the process of anti-epidemic. It will not be absent from the domestic new crown prevention and control work in the future. In the future, China will continue to implement the mainstream plan of “combining Chinese and Western medicine”, and it is expected to successfully develop more domestic small-molecule specific drugs in the future. Combining traditional Chinese medicine specific drugs will become a unique and important “Chinese plan” for domestic anti-epidemic. Pfizer’s small molecule drug industry chain and domestic small molecule drug field, focusing on: Proton, Asymchem, WuXi AppTec, Junshi Bio, Simcere, etc.; in the field of traditional Chinese medicine anti-epidemic, it is recommended to focus on: Yiling Pharmaceutical Industry, Buchang Pharmaceutical, Hongri Pharmaceutical, Chinese Traditional Medicine, Pien Tze Huang, etc.